Zoetis Inc. (ZTS)
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zoetis: Why I Decided To Invest In The Stock
Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S. declined 16% due to reported side effect concerns.
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
Zoetis Inc. (ZTS) Q2 2025 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor Relations Wetteny N.
Zoetis (ZTS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.56 per share a year ago.
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Here's Why Zoetis (ZTS) Fell More Than Broader Market
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
